NCT07725497招募中2 期
A Multicenter Phase 2 Study of Luspatercept in Patients With Anemia Due to Chronic Kidney Disease
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 30
- 试验地点
- 7
- 主要终点
- Hemoglobin (HB) improvement
研究概览
简要总结
The researchers are doing this study to test whether luspatercept works to improve hemoglobin levels in people with anemia caused by chronic kidney disease (CKD). The researchers will also test whether luspatercept is a safe treatment that causes few or mild side effects in participants.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Documentation of Anemia due to CKD
- •Patients must have a Hb ≤ 9.5 g/dL on two separate occasions within 4 weeks prior to enrollment.
- •Do not anticipate red cell transfusion within the following 4 weeks and no history of red cell transfusion in three weeks prior to enrollment.
- •Ferritin ≥100 ng/mL and iron transferrin saturation (TSAT) ≥ 20%.
- •Serum folate > 4 ng/mL
- •Serum vitamin B12 > 250 pg/mL
- •Patients may have received iron, B12 and folic acid repletion if initiated > 6 weeks prior to enrollment. Patients who are already on iron, B12 and folic acid repletion can continue throughout the trial.
- •TSH, T4 within institutional normal limits. Documentation of Chronic Kidney Disease
- •Chronic kidney disease defined as a GFR between 30-60 mL/min/1.73m2 for ≥ 3 months calculated by the 2021 CKD-EPI creatinine equation for eGFR, the 2021 CKD-EPI creatinine-cystatin C equation, or creatinine clearance measured by a 24-hour urine collection.
- •Prior Treatment with Erythrocyte Stimulating Agents (ESA)
- •Eligible patients will not have had recent (within past 3 weeks) erythrocyte stimulating agents (ESA) prior to enrollment unless they are hyporesponsive to ESA therapy.
- •Patients are eligible if they are either hyporesponsive to ESA therapy or unwilling to accept ESAs. defined by the Kidney Disease Outcomes Quality Initiative (KDOQI) as the inability to achieve/maintain a desired hemoglobin (herein defined as a hemoglobin of > 9.0 g/dL) using a maximum dose of erythropoietin (450 units/kg/week IV or 300 units/kg/week SQ or the darbepoetin equivalent using the conversion of 45,000 units/week of epoetin = 100 mcg/week of darbepoetin).
- •ECOG Performance Status of ≤ 2
- •Not Pregnant and Not Nursing Required Organ Function
- •Adequate hematologic function defined as follows:
- •Absolute neutrophil count (ANC) ≥ 1,000 cells/mm3
- •Platelets ≥ 75,000 cells/mm3
- •Adequate hepatic function defined as follows:
- •Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (patients with known Gilbert's disease who have bilirubin level ≤ 3 x ULN may be enrolled)
- •AST and ALT ≤3 x institutional ULN
- •Comorbid Conditions
- •Patients with a history of a solid organ malignancy can be included if they have been in remission for at least 12 months.
排除标准
- •Evidence of recent (within previous 4 weeks) bleeding including gastrointestinal to explain anemia.
- •Evidence of hemolysis (LDH ≥ 2 x ULN and haptoglobin below lower limit of normal)
- •Known diagnosis of myelodysplastic syndrome or any known hematologic malignancy [not including monoclonal of undetermined significance (MGUS) or monoclonal b-cell lymphocytosis (MBL)] not in remission
- •GFR < 30 mL/min/1.73m2 or on dialysis (no available data for luspatercept on HD)
- •Acute kidney injury ( ≤ 3 months)
- •Uncontrolled hypertension: repeated elevations of SBP ≥ 150 mmHg and/or DBP ≥ 100 mmHg despite adequate treatment
- •Known hemoglobinopathy.
- •Known inherited or acquired thrombophilia.
- •History of venous thromboembolism within past 2 years
- •Cerebral vascular accident within past 2 years
- •Recent (within 2 years) myocardial infarction
- •Allergy to luspatercept components
结局指标
主要结局
Hemoglobin (HB) improvement
时间窗: within 12 weeks
of at least 1.0 g/dl
次要结局
- Hemoglobin (HB) improvement(within week 28)
研究者
研究点 (7)
Loading locations...
相似试验
招募中
3 期
A study to assess the efficacy and safety of Leriglitazone in cerebral Adrenoleukodystrophy.CTRI/2025/01/079746Minoryx Therapeutics S.L40
尚未招募
不适用
A Proof of Concept, Randomized, Double Blind, Placebo Controlled Clinical Trial to Assess the Effect of GH-LS-R1 on Respiratory Health.CTRI/2025/07/089984Verisearch Lab16
尚未招募
2 期
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Pancreatic CancerNCT07301229Shanghai Henlius Biotech100
已完成
2/3 期
Clinical study on Vimosa Softgel in vaginal dryness and vaginal prolapseCTRI/2024/05/067423Abhinav Health Care Products Pvt Ltd72
招募中
2/3 期
Clinical study on TULHA tablets in participants with Delayed PeriodsCTRI/2025/12/098413Gynoveda Femtech Pvt. Ltd200